The impact of osteoporosis and vertebral compression fractures on mortality and association with pulmonary function in COPD: A meta-analysis - 02/01/22
, Fotios Sampsonas a, Vasileios Karamouzos b, George Kyriakou c, Konstantinos Parperis d, Eleni Papachristodoulou c, Costas Christophi e, f, Dimosthenis Lykouras a, Christina Kalogeropoulou g, Dimitrios Daoussis h, George Panos i, Dimitrios Velissaris j, Kyriakos Karkoulias a, Kostas Spiropoulos aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Osteoporosis is a well-known comorbidity of COPD, with an estimated prevalence of 38%. |
• | This is the first meta-analysis to evaluate the impact of osteoporosis in COPD. |
• | The presence of osteoporosis is associated with increased mortality in COPD patients. |
• | Osteoporosis is also associated with decreased FEV1 and FEV1/FVC in COPD patients. |
Abstract |
Objective |
Osteoporosis is highly prevalent among patients with chronic obstructive pulmonary disease (COPD) and most commonly presents as a vertebral compression fracture (VCF). Our objective was to quantify the effect of osteoporosis and VCFs on the mortality and pulmonary function tests (PFTs), such as forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), of patients with COPD.
Methods |
A PubMed/Medline search was conducted using the search terms “chronic obstructive pulmonary disease”, “osteoporosis” and “vertebral compression fracture”. Meta-analyses were conducted to evaluate the differences in mortality and PFTs between patients with COPD with and without osteoporosis or VCFs, according to PRISMA guidelines. PROSPERO registration: CRD42019120335.
Results |
Of the 896 abstracts identified, 27 studies describing 7662 patients with COPD of which 1883 (24.6%) had osteoporosis or VCFs, were included. Random effects model analysis demonstrated that patients with COPD and osteoporosis or VCFs had an increased OR for mortality of 2.40 (95% CI: 1.24; 4.64, I2=89%, P<0.01), decreased FEV1/FVC with a mean difference of −4.80% (95% CI: −6.69; −2.90, I2=83%, P<0.01) and decreased FEV1, with a mean difference of −4.91% (95% CI: −6.51; −3.31, I2=95%, P<0.01) and −0.41 L (95% CI: −0.59; −0.24, I2=97%, P<0.01), compared to control subjects. Apart from FEV1 (liters) in subgroup 1 (P=0.06), all subgroup analyses found significant differences between groups, as did sensitivity analysis of low risk of bias studies.
Conclusion |
Osteoporosis and VCFs are associated with a significant reduction in survival and pulmonary function among patients with COPD.
Le texte complet de cet article est disponible en PDF.Keywords : Chronic obstructive pulmonary disease, Survival, Osteoporosis
Plan
Vol 89 - N° 1
Article 105249- janvier 2022 Retour au numéro
Article précédent
- Tight control and treat-to-target in axial spondyloarthritis. Where are we?
- Daniel Wendling, Pascal Claudepierre, Philippe Goupille, Thao Pham, Clément Prati
- How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis
- Frank Buttgereit, Andriko Palmowski
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?